Company intelligence / Profile preview

Crinetics Pharmaceuticals

San Diego, California, United Statescrinetics.com ↗

Ownership: Public · CRNX
Development stage: NDA

Overview

Crinetics has submitted an NDA for paltusotine for acromegaly treatment. The company has reported positive results from Phase 2 studies of paltusotine in carcinoid syndrome and atumelnant in congenital adrenal hyperplasia. Multiple programs are advancing through preclinical and clinical development.

Therapeutic areas: OncologyEndocrinologyNephrology
Modalities: Small moleculesNonpeptide drug conjugates
Industry: Biotech

Drug pipeline

7 assets

paltusotine

Approved

6 more assets in the full pipeline.

Request access →

Partnerships

Collaboration with Radionetics Oncology

Financials

Market cap: $9B
Total revenue: $25.1M
Enterprise value: $7.8B

Beyond the preview

Go deeper on Crinetics Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Crinetics Pharmaceuticals.

Explore the full profile